Navigation Links
Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
Date:9/8/2008

ROCKVILLE, Md., Sept. 8 /PRNewswire-FirstCall/ -- Neuralstem Inc., CEO, Richard Garr, will be a featured panelist discussing stem cells and ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at the 2008 World Stem Cell Summit in Madison, Wisconsin, on September 22, at 2:00 CDT. In a presentation prior to the panel, Mr. Garr will talk about Neuralstem's plans for an ALS trial and give an update of the Company's filing status with the FDA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

The World Stem Cell Summit (http://www.worldstemcellsummit.com) is sponsored by the Genetics Policy Institute, the University of Wisconsin- Madison Stem Cell & Regenerative Medicine Center and WiCell Research Institute, Inc.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego. The Company expects to file its first IND (Investigational New Drug) application with the FDA for ALS in the fall.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended June 30, 2008.


'/>"/>
SOURCE Neuralstem Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Shares Accepted for Trading on Amex(R)
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Neuralstem Sues StemCells, Inc. Over New Patent
6. Neuralstem Responds to New StemCells, Inc. Lawsuit
7. Neuralstem Fills Key Product Development Position
8. Neuralstem Reports Second Quarter Financial Results and Highlights
9. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
10. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
11. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Washington, USA (PRWEB) , ... December 02, 2016 ... ... role of innovative U.S.-owned and -operated small businesses in federally funded research and ... SPIE, the international society for optics and photonics . , As part of ...
(Date:12/2/2016)... ... 02, 2016 , ... In anticipation of AxioMed’s exclusive cleanroom ... company President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. ... Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received ...
(Date:12/2/2016)... Dec. 2, 2016 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced the appointment of ... industry consultant, and private healthcare investor, to its Board ... leader with clinical and strategic experience at the highest ... and CEO. "As one of the world,s leading orthopedic ...
(Date:12/2/2016)... ... , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing the global ... solution for tracking and securing medications at booth 676 at the ASHP Midyear ... has a proven solution for tracking medications via its system from pharmacy to ...
Breaking Biology Technology:
(Date:11/14/2016)... -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, ... use in challenging operating environments, announced its results for ... hold a conference call to discuss these results on ... below). Key Recent Accomplishments ... to acquire Vislink Communication Systems. The purchase is expected ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):